Square Pharmaceuticals PLC.

DSE:SQURPHARMA Stock Report

Market Cap: ৳195.4b

Square Pharmaceuticals Past Earnings Performance

Past criteria checks 4/6

Square Pharmaceuticals has been growing earnings at an average annual rate of 10%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 9.6% per year. Square Pharmaceuticals's return on equity is 17.3%, and it has net margins of 31%.

Key information

10.0%

Earnings growth rate

10.0%

EPS growth rate

Pharmaceuticals Industry Growth11.0%
Revenue growth rate9.6%
Return on equity17.3%
Net Margin31.0%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Square Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DSE:SQURPHARMA Revenue, expenses and earnings (BDT Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2472,26622,37514,9650
30 Sep 2470,03721,01714,7550
30 Jun 2470,10120,92614,1680
31 Mar 2465,34520,23812,6290
31 Dec 2364,00419,59911,4950
30 Sep 2364,48919,48013,5120
30 Jun 2360,70818,98011,6890
31 Mar 2362,02018,85613,7120
31 Dec 2260,78219,14313,0980
30 Sep 2258,79118,68012,5970
30 Jun 2257,59818,15712,1180
31 Mar 2256,71318,52611,1810
31 Dec 2154,83417,81910,8250
30 Sep 2153,00417,01210,4250
30 Jun 2150,70315,94710,0340
31 Mar 2149,02114,4849,4060
31 Dec 2048,39514,2379,2050
30 Sep 2047,15813,9339,0230
30 Jun 2045,87613,3548,8550
31 Mar 2046,36013,7338,7750
31 Dec 1945,13813,2368,4830
30 Sep 1944,78512,8318,2660
30 Jun 1944,03412,6468,0380
31 Mar 1942,32212,1687,4540
31 Dec 1841,25212,0257,4790
30 Sep 1840,32811,7547,2080
30 Jun 1839,65411,5946,9960
31 Mar 1839,47411,6676,8490
31 Dec 1739,13111,6226,4800
30 Sep 1737,97811,2226,3300
30 Jun 1736,54310,6376,1930
31 Mar 1735,58410,3306,1020
31 Dec 1634,5349,8935,4900
30 Sep 1633,4489,6395,3150
30 Jun 1633,0749,1995,3710
31 Dec 1529,6427,7704,9660
30 Sep 1528,4007,0914,7920
30 Jun 1527,5316,4114,7110
31 Mar 1525,9796,0325,0910
31 Dec 1425,8585,0604,6320
30 Sep 1425,5115,1224,4470
30 Jun 1424,1765,0024,3370
31 Mar 1423,2684,9454,1620

Quality Earnings: SQURPHARMA has a high level of non-cash earnings.

Growing Profit Margin: SQURPHARMA's current net profit margins (31%) are higher than last year (30.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SQURPHARMA's earnings have grown by 10% per year over the past 5 years.

Accelerating Growth: SQURPHARMA's earnings growth over the past year (14.2%) exceeds its 5-year average (10% per year).

Earnings vs Industry: SQURPHARMA earnings growth over the past year (14.2%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: SQURPHARMA's Return on Equity (17.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/19 17:05
End of Day Share Price 2025/03/19 00:00
Earnings2024/12/31
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Square Pharmaceuticals PLC. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
S M Toufique ImranBRAC EPL Stock Brokerage Ltd
Asif KhanEDGE Research & Consulting
Tanay RoyIDLC Securities Limited